Research note · 2 October 2026
Pfizer Inc PFE
SHORT price $27.80 · base case $16.49 · expected +48% over 540 days
The call
Pfizer is trading at $27.80, significantly above the base-case DCF value of $16.49, reflecting a 36.58x trailing P/E that masks underlying structural headwinds. The elevated multiple is an accounting artifact driven by $4.3 billion in Q2 2026 intangible impairments and ongoing restructuring, which suppresses TTM GAAP EPS to $0.76. Despite generating $13,117.2 million in trailing twelve-month FCFF, the company faces steep revenue erosion from $1.5 billion in 2026 patent expiries, approximately $1 billion in IRA Medicare Part D redesign impacts, and intense pricing pressure from MCOs and PBMs.
Why the opportunity exists, in the desk's view: a narrative overshoot.
What decides the case
- Patent cliff magnitude vs. pipeline offset
- IRA Medicare Part D Redesign pricing pressure
- R&D productivity and M&A integration
What breaks the case
| Shock to the base case | Value per share | vs price |
|---|---|---|
| Base case as planned | $16.49 | -41% |
| Starting cash flow 10% higher | $19.10 | -31% |
| Growth 5 points higher every year | $23.00 | -17% |
| Discount rate 100bp higher | $13.25 | -52% |
| Starting cash flow 10% lower | $13.88 | -50% |
| Growth 5 points lower every year | $11.13 | -60% |
| Cost of debt 200bp higher | $14.92 | -46% |
The base case equals the price at a 6.1% discount rate, or if every year's growth were +8.2% points different. Thresholds, not forecasts.
Model-authored research with an editorial gate; every figure traces to the filing or a stated assumption and every calculation was reproduced before publication. Not investment advice. Do not redistribute.